- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07739004
Triage Performance and Physiological Predictors of Serious Illness in Febrile Children in the Pediatric Emergency Department (PEDTRIAGE)
3. august 2026 opdateret af: Yılmaz Seçilmiş, TC Erciyes University
Triage Performance and Physiological Parameters Predicting Serious Illness in Children Presenting With Fever to the Pediatric Emergency Department: A Multicenter Prospective Cohort Study
This multicenter prospective observational cohort study evaluates how well the initial triage category assigned by the Turkish Ministry of Health three-level color-coded triage system (Red-Yellow-Green) predicts serious clinical outcomes in children aged 0-18 years who present with fever to pediatric emergency departments.
The study additionally assesses whether physiological parameters recorded at triage (heart rate, respiratory rate, oxygen saturation, capillary refill time, AVPU level of consciousness, and general appearance) provide independent and incremental prognostic value beyond the assigned triage category.
Ten centers across Turkey will enroll consecutive eligible febrile children over a 3-month period.
Routine clinical care and triage decisions are not altered by the study.
The primary outcome is a composite serious clinical outcome.
The study is reported in accordance with the STROBE and TRIPOD statements.
Studieoversigt
Status
Rekruttering
Intervention / Behandling
Detaljeret beskrivelse
Design: Prospective, multicenter, observational cohort study.
Setting: 10 pediatric emergency departments in Turkey; Erciyes University is the coordinating center.
Population: consecutive children aged 0-18 years presenting with fever (>=38.0
C at triage or history of fever within the preceding 24 hours).
Trauma presentations, elective visits, records with missing triage data, and re-attendances within 72 hours for the same episode are excluded (only the first visit is included).
Physiological parameters are recorded on a standardized triage form and are NOT used to change the triage decision.
Heart rate is modeled as a continuous variable with age-based z-scores (Fleming reference ranges), with body temperature always included as a covariate to distinguish fever-related from pathological tachycardia.
Sample size: assuming a serious-outcome (composite) event rate of ~3%, approximately 3000 children (~90 events) are targeted (~300 per center over 3 months), following Riley et al. (BMJ 2020) criteria (target R2>=0.15,
calibration slope>=0.90) in addition to the EPV>=10 rule.
A pilot evaluation at the end of the first month recalculates the true event rate.
Analysis: Triage performance is summarized with sensitivity, specificity, PPV, NPV, LR+ and LR- with 95% CIs.
A pre-specified 3-step mixed-effects logistic regression (centers as random effect) compares Model 1 (triage category only), Model 2 (+ physiological parameters and temperature), and Model 3 (+ laboratory variables in the tested subgroup).
Discrimination (ROC/AUC, DeLong test, NRI, IDI) and calibration (calibration curve and slope, O/E ratio) are reported.
Missing data are handled by multiple imputation (m=20).
Undersøgelsestype
Observationel
Tilmelding (Anslået)
3000
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Yilmaz Secilmis, MD
- Telefonnummer: +905063013174
- E-mail: yilmazsecilmis@erciyes.edu.tr
Studiesteder
-
-
-
Adana, Tyrkiet (Türkiye)
- Rekruttering
- Adana City Training and Research Hospital
-
Kontakt:
- Saadetnur Bozgeyik Aksoy, MD
- Telefonnummer: +90 05077185767
- E-mail: saadetnb@gmail.com
-
Adana, Tyrkiet (Türkiye)
- Rekruttering
- Cukurova University Faculty of Medicine
-
Kontakt:
- Sevcan Bilen, MD
- Telefonnummer: +90 532 276 50 84
- E-mail: svcnbln@hotmail.com
-
Antalya, Tyrkiet (Türkiye)
- Rekruttering
- Akdeniz University Faculty of Medicine
-
Kontakt:
- Ozlem Tolu Kendir, MD
- Telefonnummer: +90 505 304 98 09
- E-mail: otolu80@yahoo.com
-
Eskişehir, Tyrkiet (Türkiye)
- Rekruttering
- Osmangazi University Faculty of Medicine
-
Kontakt:
- Emre Gungor, MD
- Telefonnummer: +90 506 425 52 40
- E-mail: emregungormd@gmail.com
-
Istanbul, Tyrkiet (Türkiye)
- Rekruttering
- Kartal Dr. Lutfi Kirdar City Hospital
-
Kontakt:
- Feyza Esen
- Telefonnummer: +90 505 724 32 56
- E-mail: feyzahusrevoglu@hotmail.com
-
Izmir, Tyrkiet (Türkiye)
- Rekruttering
- Dokuz Eylul University Faculty of Medicine
-
Kontakt:
- Emel Ulusoy
- Telefonnummer: +90 506 914 00 08
- E-mail: ulusoy.emel@deu.edu.tr
-
Kayseri, Tyrkiet (Türkiye)
- Rekruttering
- Kayseri City Hospital
-
Kontakt:
- Murat Dogan, MD
- Telefonnummer: +905059025999
- E-mail: doktormurat033@hotmail.com
-
Manisa, Tyrkiet (Türkiye)
- Rekruttering
- Celal Bayar University Faculty of Medicine
-
Kontakt:
- Alkan Bal, MD
- Telefonnummer: +90 505 815 01 33
- E-mail: balalkan@hotmail.com
-
Tokat Province, Tyrkiet (Türkiye)
- Rekruttering
- Tokat University Faculty of Medicine
-
Kontakt:
- Seda Gumustekin Bilgin
- Telefonnummer: +90 554 206 60 04
- E-mail: dr.seda.cocukacil@gmail.com
-
-
Talas
-
Kayseri, Talas, Tyrkiet (Türkiye), 38039
- Rekruttering
- Erciyes University Faculty of Medicine
-
Kontakt:
- Yilmaz Secilmis, MD
- Telefonnummer: +905063013174
- E-mail: yilmazsecilmis@erciyes.edu.tr
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
Tager imod sunde frivillige
Ingen
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Consecutive children aged 0-18 years presenting with fever to the participating pediatric emergency departments during the study period.
Beskrivelse
Inclusion Criteria:
- Age 0-18 years
- Presentation to the pediatric emergency department
- Fever >=38.0 C at triage OR history of fever within the preceding 24 hours
Exclusion Criteria:
- Presentation due to trauma
- Elective visits
- Missing triage data
- Re-attendance within 72 hours for the same episode (only the first visit is included)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Febrile children in the pediatric emergency department
Children aged 0-18 years presenting with fever (>=38.0
C at triage or history of fever within the preceding 24 hours) to a participating pediatric emergency department during the 3-month study period.
All undergo routine triage with the Ministry of Health three-level color-coded system; triage decisions and clinical care are not altered by the study.
|
At presentation, each child is assigned a triage category (Red, Yellow, or Green) by the triage nurse using the Turkish Ministry of Health three-level color-coded system, and physiological parameters (heart rate, respiratory rate, oxygen saturation, capillary refill time, AVPU level of consciousness, and general appearance) are recorded on a standardized triage form.
This reflects routine care and is not modified for the study.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Composite serious clinical outcome
Tidsramme: 30 Dys
|
Presence of at least one of: intensive care unit admission; invasive or non-invasive mechanical ventilation; vasopressor/inotropic therapy; culture- or sterile-body-fluid-confirmed invasive bacterial infection; 30-day mortality.
|
30 Dys
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Hospital admission with intravenous antibiotics
Tidsramme: Up to 30 days
|
Hospital admission with intravenous antibiotic treatment for at least 24 hours.
|
Up to 30 days
|
|
Sepsis protocol activation
Tidsramme: Index ED visit (day 1)
|
Activation of an institutional sepsis protocol during the index emergency department visit.
|
Index ED visit (day 1)
|
|
Intravenous fluid bolus of at least 20 mL/kg
Tidsramme: Index ED visit (day 1)
|
Administration of an intravenous fluid bolus of at least 20 mL/kg during the index emergency department visit.
|
Index ED visit (day 1)
|
|
Unplanned re-attendance with admission
Tidsramme: 72 hours
|
Re-attendance within 72 hours followed by admission to a ward or intensive care unit.
|
72 hours
|
|
All-cause hospital ward admission
Tidsramme: Index ED visit (day 1)
|
Admission to a hospital ward for any cause.
|
Index ED visit (day 1)
|
|
Undertriage rate
Tidsramme: 30 days
|
Proportion of Green-triaged patients who develop the primary composite outcome.
|
30 days
|
|
Overtriage rate
Tidsramme: 30 days
|
Proportion of Red-triaged patients who do not develop the primary composite outcome.
|
30 days
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Yilmaz Secilmis, TC Erciyes University
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007 Oct 20;370(9596):1453-7. doi: 10.1016/S0140-6736(07)61602-X.
- Fleming S, Thompson M, Stevens R, Heneghan C, Pluddemann A, Maconochie I, Tarassenko L, Mant D. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet. 2011 Mar 19;377(9770):1011-8. doi: 10.1016/S0140-6736(10)62226-X.
- Riley RD, Ensor J, Snell KIE, Harrell FE Jr, Martin GP, Reitsma JB, Moons KGM, Collins G, van Smeden M. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020 Mar 18;368:m441. doi: 10.1136/bmj.m441. No abstract available.
- Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015 Jan 6;162(1):55-63. doi: 10.7326/M14-0697.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
28. juli 2026
Primær færdiggørelse (Anslået)
1. november 2026
Studieafslutning (Anslået)
1. december 2026
Datoer for studieregistrering
Først indsendt
27. juli 2026
Først indsendt, der opfyldte QC-kriterier
27. juli 2026
Først opslået (Faktiske)
31. juli 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
5. august 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
3. august 2026
Sidst verificeret
1. august 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ERU-PEDTRIAGE-2026
- 2026/382 (Anden identifikator: Erciyes University Clinical Research Ethics Committee)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
Individual participant data will not be shared publicly.
De-identified data may be made available from the coordinating center on reasonable request, subject to approval by the coordinating ethics committee and a data-sharing agreement, in accordance with institutional and national data-protection regulations.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .